PreTRM for Healthcare Providers An Instrumental Prenatal Assessment For Your Practice
The PreTRM® Test provides you with your patients’ risk for spontaneous premature birth in asymptomatic singleton pregnancies. This pivotal information — provided in the form of an individual risk percentage — gives you sufficient time and vital insights to make informed treatment decisions with your patients.
One in 10 Babies is Born Too Soon
With an incidence of one in ten pregnancies1, preterm birth is considered by many medical experts to be a public health crisis. The emotional, financial, and long-term health implications for preterm babies and their families can be overwhelming. Up until this point, ways to accurately predict the risk of a preterm delivery have been limited, with only a small percentage of high risk patients identified through clinical or demographic risk factors.
Limitations of Traditional Preterm Birth Screening Methods
Until recently, clinicians have had limited resources for predicting the risk of spontaneous preterm birth. Up to half of all pregnant women who deliver prematurely have no known risk factors.2,3
Answers Provided by Proteomics
Given the limitations of current risk factors to predict the risk of premature birth, scientists at Sera Prognostics set out to discover a biomarker prediction that would provide an early individual risk of assessment for spontaneous preterm birth. Researchers discovered that two proteins combined with biometric variables provides highly accurate prediction of spontaneous preterm birth in asymptomatic singleton pregnancies.
Hear what your peers are saying
References
- Hamilton BE, et al. Births: Provisional data for 2020. Vital Statistics Rapid Release; no 12. Hyattsville, MD: National Center for Health Statistics. May 2021.
- Institute of Medicine Committee on Understanding Premature Birth and Assuring Healthy Outcomes. Preterm Birth: Causes, Consequences, and Prevention. Behrman RE, Butler AS, eds. Washington (DC): National Academies Press (US)
- Iams JD, et al. Prevention of Preterm Parturition N Engl J Med 2014;370:254-61. DOI: 10.1056/NEJMcp1103640
- Matthew K. Hoffman, Carrie Kitto, Zugui Zhang, et al. Neonatal outcomes after proteomic biomarker-guided intervention: the AVERT PRETERM TRIAL. medRxiv 2023.09.13.23295503; doi: https://doi.org/10.1101/2023.09.13.23295503